company background image
XOMA

XOMA NasdaqGM:XOMA Stock Report

Last Price

US$20.84

Market Cap

US$238.0m

7D

0.2%

1Y

-37.4%

Updated

01 Jul, 2022

Data

Company Financials +
XOMA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance5/6
Financial Health6/6
Dividends0/6

XOMA Stock Overview

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific.

Rewards

Earnings are forecast to grow 58.06% per year

Earnings grew by 113.2% over the past year

Risk Analysis

No risks detected for XOMA from our risk checks.

XOMA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for XOMA
Historical stock prices
Current Share PriceUS$20.84
52 Week HighUS$37.50
52 Week LowUS$16.96
Beta1.08
1 Month Change22.16%
3 Month Change-25.86%
1 Year Change-37.42%
3 Year Change37.83%
5 Year Change199.00%
Change since IPO-99.71%

Recent News & Updates

Shareholder Returns

XOMAUS BiotechsUS Market
7D0.2%0.07%-2.5%
1Y-37.4%-25.1%-21.2%

Return vs Industry: XOMA underperformed the US Biotechs industry which returned -27% over the past year.

Return vs Market: XOMA underperformed the US Market which returned -21.7% over the past year.

Price Volatility

Is XOMA's price volatile compared to industry and market?
XOMA volatility
XOMA Average Weekly Movement11.7%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: XOMA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: XOMA's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198112Jim Nealhttps://www.xoma.com

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.

XOMA Fundamentals Summary

How do XOMA's earnings and revenue compare to its market cap?
XOMA fundamental statistics
Market CapUS$238.01m
Earnings (TTM)US$12.04m
Revenue (TTM)US$40.89m

19.8x

P/E Ratio

5.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
XOMA income statement (TTM)
RevenueUS$40.89m
Cost of RevenueUS$166.00k
Gross ProfitUS$40.73m
Other ExpensesUS$28.68m
EarningsUS$12.04m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)1.05
Gross Margin99.59%
Net Profit Margin29.45%
Debt/Equity Ratio0%

How did XOMA perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is XOMA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XOMA?

Other financial metrics that can be useful for relative valuation.

XOMA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.7x
Enterprise Value/EBITDA6.8x
PEG Ratio0.3x

Price to Earnings Ratio vs Peers

How does XOMA's PE Ratio compare to its peers?

XOMA PE Ratio vs Peers
The above table shows the PE ratio for XOMA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average12.1x
LJPC La Jolla Pharmaceutical
15.2x42.2%US$79.7m
CPRX Catalyst Pharmaceuticals
16.1x12.2%US$725.6m
CLNN Clene
9.6x82.7%US$160.7m
ORGO Organogenesis Holdings
7.6x8.5%US$645.7m
XOMA XOMA
19.8x58.1%US$238.0m

Price-To-Earnings vs Peers: XOMA is expensive based on its Price-To-Earnings Ratio (19.8x) compared to the peer average (12.1x).


Price to Earnings Ratio vs Industry

How does XOMA's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Earnings vs Industry: XOMA is expensive based on its Price-To-Earnings Ratio (19.8x) compared to the US Biotechs industry average (15.4x)


Price to Earnings Ratio vs Fair Ratio

What is XOMA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XOMA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio19.8x
Fair PE Ratio36.6x

Price-To-Earnings vs Fair Ratio: XOMA is good value based on its Price-To-Earnings Ratio (19.8x) compared to the estimated Fair Price-To-Earnings Ratio (36.6x).


Share Price vs Fair Value

What is the Fair Price of XOMA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate XOMA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate XOMA's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: XOMA is good value based on its PEG Ratio (0.3x)


Discover undervalued companies

Future Growth

How is XOMA forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


58.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XOMA's forecast earnings growth (58.1% per year) is above the savings rate (1.9%).

Earnings vs Market: XOMA's earnings (58.1% per year) are forecast to grow faster than the US market (13.6% per year).

High Growth Earnings: XOMA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: XOMA's revenue (21.4% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: XOMA's revenue (21.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if XOMA's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has XOMA performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


49.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: XOMA has high quality earnings.

Growing Profit Margin: XOMA's current net profit margins (29.4%) are higher than last year (19.5%).


Past Earnings Growth Analysis

Earnings Trend: XOMA has become profitable over the past 5 years, growing earnings by 49.3% per year.

Accelerating Growth: XOMA's earnings growth over the past year (113.2%) exceeds its 5-year average (49.3% per year).

Earnings vs Industry: XOMA earnings growth over the past year (113.2%) exceeded the Biotechs industry 98.2%.


Return on Equity

High ROE: XOMA's Return on Equity (14.9%) is considered low.


Discover strong past performing companies

Financial Health

How is XOMA's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: XOMA's short term assets ($89.6M) exceed its short term liabilities ($7.9M).

Long Term Liabilities: XOMA's short term assets ($89.6M) exceed its long term liabilities ($11.3M).


Debt to Equity History and Analysis

Debt Level: XOMA is debt free.

Reducing Debt: XOMA currently has no debt however we can't compare to 5 years ago as we have no data for that period.

Debt Coverage: XOMA has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: XOMA has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is XOMA current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate XOMA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate XOMA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XOMA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XOMA's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as XOMA has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.4yrs

Average board tenure


CEO

Jim Neal (66 yo)

5.5yrs

Tenure

US$3,510,795

Compensation

Mr. James R. Neal, also known as Jim, serves as Director at Palisade Bio, Inc. (Alternate name: Leading BioSciences Inc) since October 30, 2018 and serves as its Chairman of the Board since April 27, 2021...


CEO Compensation Analysis

Compensation vs Market: Jim's total compensation ($USD3.51M) is above average for companies of similar size in the US market ($USD1.79M).

Compensation vs Earnings: Jim's compensation has increased by more than 20% in the past year.


Board Members

Experienced Board: XOMA's board of directors are considered experienced (5.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

XOMA Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: XOMA Corporation
  • Ticker: XOMA
  • Exchange: NasdaqGM
  • Founded: 1981
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$238.012m
  • Shares outstanding: 11.42m
  • Website: https://www.xoma.com

Number of Employees


Location

  • XOMA Corporation
  • 2200 Powell Street
  • Suite 310
  • EmeryVille
  • California
  • 94608
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/01 00:00
End of Day Share Price2022/07/01 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.